🇺🇸 FDA
Patent

US 11464801

Compositions and methods for treating cancer with anti-CD33 immunotherapy

granted A61KA61K2039/505A61K2239/25

Quick answer

US patent 11464801 (Compositions and methods for treating cancer with anti-CD33 immunotherapy) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon Oct 06 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Secretary, Department of Health and Human Services
Grant date
Tue Oct 11 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Oct 06 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
15
CPC classes
A61K, A61K2039/505, A61K2239/25, A61K2239/38, A61K39/39558